Evidence map›Paper›PMID 23066162›Full record

ArticleThe Journal of infectious diseases2012

Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection.

Theodoros Kelesidis, Michelle A Kendall, Otto O Yang, Howard N Hodis, Judith S Currier

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 4 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 4 syntheses or guidelines pooled it, 213 citations in OpenAlex.

  1. Pooled it
  2. The Impact of Human Immunodeficiency Virus Infection on Gut Microbiota α-Diversity: An Individual-level Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Brief Report: Zinc Supplementation and Inflammation in Treated HIV.Journal of acquired immune deficiency syndromes (1999) · 2019
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Trial

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Theodoros KelesidisDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA 90035, USA.
Michelle A Kendall
Otto O Yang
Howard N Hodis
Judith S Currier
Cancer Research And Biostatistics · USOffice of Infectious Diseases · USUniversity of California, Los Angeles · USUniversity of Southern California · US

Funding

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MITSUYASU, RONALD T. · 1991 to 2018
$39.9M
CVD and Metabolic Complications of HIV/AIDS Data Coordinating CenterR01HL095126 · NHLBI · UNIVERSITY OF WASHINGTON · PI KRONMAL, RICHARD A · 2008 to 2012
$5.9M
Prospective Evaluation of Antiviral Therapy and Cardiac HealthR01HL095132 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CURRIER, JUDITH S., STEIN, JAMES H · 2008 to 2012
$4.0M
Optimizing Antiretroviral Therapy in HIV K24AI056933 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CURRIER, JUDITH S. · 2003 to 2013
$1.4M
NHLBI NIH HHS 5R01HL095126NHLBI NIH HHS R01 HL095126NHLBI NIH HHS R01 HL095132NIAID NIH HHS AI056933NIAID NIH HHS AI068634NIAID NIH HHS AI28697NIAID NIH HHS K24 AI056933NIAID NIH HHS P30 AI028697NIAID NIH HHS U01 AI068634NIAID NIH HHS UM1 AI068634
6 · The paper itself

Abstract

backgroundThe relationships between soluble CD14 (sCD14), endotoxin (lipopolysaccharide [LPS]), and progression of atherosclerosis have not been defined in human immunodeficiency virus (HIV) infection.

methodsWe retrospectively assessed serum sCD14 and LPS levels of 91 subjects in a prospective 3-year study of carotid artery intima-media thickness (CIMT) (AIDS Clinical Trials Group [ACTG] 5078), where subjects were enrolled as risk factor-controlled triads of HIV-uninfected (n = 36) and HIV-infected individuals with (n = 29) or without (n = 26) protease inhibitor (PI)-based therapy for ≥2 years. The primary end point was the yearly rate of change of CIMT (ΔCIMT).

resultsIn multivariate analysis of the HIV-infected subjects, each 1 µg/mL above the mean of baseline serum sCD14 corresponded to an additional 1.52 µm/y (95% confidence interval, .07-2.98; P = .04) in the ΔCIMT. Every 100 pg/mL above the mean of baseline serum LPS corresponded to an additional 0.49 µm/y (95% confidence interval, .18-.81; P = .003) in the ΔCIMT. However, in univariate analysis in the HIV-uninfected group sCD14 (P = .33) and LPS (P = .27) levels were not associated with higher ΔCIMT. HIV infection and PI therapy were not associated with baseline serum LPS and sCD14 levels (P > .1).

conclusionsOur data are among the first to suggest that serum biomarkers of microbial translocation (LPS) and macrophage activation (sCD14) predict subclinical atherosclerosis progression in HIV-infected persons.

Indexed as

HIV-1AdultAnti-HIV AgentsAtherosclerosisBacterial TranslocationBiomarkersCohort StudiesFemaleHIV InfectionsHumansLipopolysaccharide ReceptorsLipopolysaccharidesMacrophage ActivationMaleMiddle AgedProtease InhibitorsAnti-HIV AgentsBiomarkersLipopolysaccharide ReceptorsLipopolysaccharidesProtease Inhibitors

Identifiers

PMID23066162
PMCPMC3475633
OpenAlexW2131142211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.